Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Molecular mechanisms of proteasome assembly.

Murata S, Yashiroda H, Tanaka K.

Nat Rev Mol Cell Biol. 2009 Feb;10(2):104-15. doi: 10.1038/nrm2630. Review.

PMID:
19165213
2.

The fast-growing business of SUMO chains.

Ulrich HD.

Mol Cell. 2008 Nov 7;32(3):301-5. doi: 10.1016/j.molcel.2008.10.010. Review.

3.

Treatment of myeloma--are we making progress?

Durie BG.

N Engl J Med. 2008 Aug 28;359(9):964-6. doi: 10.1056/NEJMe0805176. No abstract available.

PMID:
18753654
4.

Marked for death.

Petrie K, Zelent A.

Nat Cell Biol. 2008 May;10(5):507-9. doi: 10.1038/ncb0508-507. No abstract available.

PMID:
18454129
5.

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.

Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT.

Nat Cell Biol. 2008 May;10(5):538-46. doi: 10.1038/ncb1716. Epub 2008 Apr 13.

PMID:
18408734
6.

Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.

Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de Thé H.

Nat Cell Biol. 2008 May;10(5):547-55. doi: 10.1038/ncb1717. Epub 2008 Apr 13.

PMID:
18408733
7.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL.

Cancer Cell. 2007 Aug;12(2):131-44.

8.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

9.
10.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B.

Blood. 2007 Mar 15;109(6):2276-84. Epub 2006 Nov 14.

11.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr.

Blood. 2007 Feb 15;109(4):1692-700. Epub 2006 Oct 5.

12.

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC.

Clin Cancer Res. 2006 Oct 1;12(19):5887-94.

13.

Ubiquitin and ubiquitin-like proteins in cancer pathogenesis.

Hoeller D, Hecker CM, Dikic I.

Nat Rev Cancer. 2006 Oct;6(10):776-88. Review.

PMID:
16990855
14.

The molecular classification of multiple myeloma.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 15;108(6):2020-8. Epub 2006 May 25.

15.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J.

N Engl J Med. 2006 Mar 9;354(10):1021-30.

16.

Human MMS21/NSE2 is a SUMO ligase required for DNA repair.

Potts PR, Yu H.

Mol Cell Biol. 2005 Aug;25(16):7021-32.

17.

Novel biological therapies for the treatment of multiple myeloma.

Richardson PG, Mitsiades CS, Hideshima T, Anderson KC.

Best Pract Res Clin Haematol. 2005;18(4):619-34. Review.

PMID:
16026741
18.

Regulated protein degradation.

Varshavsky A.

Trends Biochem Sci. 2005 Jun;30(6):283-6. Review. No abstract available.

PMID:
15950869
19.

International staging system for multiple myeloma.

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J.

J Clin Oncol. 2005 May 20;23(15):3412-20. Epub 2005 Apr 4. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve].

20.

Sumoylation: a new wrestler in the DNA repair ring.

Aragón L.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4661-2. Epub 2005 Mar 21. No abstract available.

Supplemental Content

Support Center